Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70

Ashvini Keshavan, J. Pannee, T. K. Karikari, J. Lantero Rodriguez, N. J. Ashton, J. M. Nicholas, D. M. Cash, W. Coath, C.A. Lane, T. D. Parker, K. Lu, S. M. Buchanan, S. E. Keuss, S. James, H. Murray-Smith, A. Wong, A. Barnes, J. C. Dickson, A. Heslegrave, E. Portelius, M. Richards, N. C. Fox, H. Zetterberg, K. Blennow and J. M. Schott

BRAIN doi:10.1093/brain/awaa403

Selezionato dal Lettore: Antonio Farina - Università degli Studi di Firenze - Neurologia

MOTIVATION: researchers found that a relatively simple blood test, liquid chromatography-mass spectrometry (LC-MS) measure of plasma amyloid-beta, predicted with a good accuracy cerebral amyloid-b deposition detected by PET in a large cohort of dementia-free individuals. Early identification and recruitment in clinical trials of amyloid-beta positive individuals could significantly improve disease modifying therapies addressing Alzheimer patients at preclinical stage.